Company
Headquarters: Taichung, Taiwan
Employees: 94
TW$15.58 Billion
TWD as of July 1, 2024
US$478.5 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Ever Supreme Bio Technology Co., Ltd engages in the research and development of cell gene therapies based on immune cells and stem cells. Its products in development include UMSC01, a drug candidate in Phase 2 clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase 3 clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product in Phase 1 clinical trials for use in the treatment of triple-negative breast cancer; and gene modified mesenchymal stem cells and fucoidan nanoparticles for use in the treatment of malignant tumor. The company was founded in 2016 and is based in Taichung, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Ever Supreme Bio Technology Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6712 wb_incandescent